Out-license Agreements - Additional Information (Detail) - USD ($)	1 Months Ended				12 Months Ended
	Jan. 31, 2022	Oct. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
License, Collaboration and Manufacturing Agreements [Line Items]
License and collaboration revenue					$ 20,340,000	$ 0	$ 0
Years of manufacturing and supplying cost					7 years
Bayer License Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
Upfront cash payment received				$ 45,000,000.0
Additional upfront reimbursement payment for research and process development				15,000,000.0
Additional upfront cash payment entitle to receive for translational activities, invoiced amount				$ 1,300,000		1,300,000
Royalty eligible to receive term after first commercial sale				12 years
Determined upfront payment for license in order to evaluate transaction price				$ 45,000,000.0
Determined research and process development activities in order to evaluate transaction price				15,000,000.0
Determined additional specified translational activities in order to evaluate transaction price				5,000,000.0
Determined fee constituted entire consideration included in transaction price					$ 13,100,000
Deferred revenue					51,500,000
Development or sales-based milestone payments earned or received					0
Bayer License Agreement | Current Liabilities
License, Collaboration and Manufacturing Agreements [Line Items]
Deferred revenue					40,800,000
Bayer License Agreement | Long-Term Liabilities
License, Collaboration and Manufacturing Agreements [Line Items]
Deferred revenue					$ 10,700,000
Bayer License Agreement | Maximum
License, Collaboration and Manufacturing Agreements [Line Items]
Additional upfront cash payment entitle to receive for translational activities				5,000,000.0		5,000,000.0
Aggregate milestone payments entitle to receive upon achieving certain development, regulatory and commercial milestones				610,000,000.0		610,000,000.0
Bayer Technology Transfer Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
License agreement percentage			20.00%
License agreement amount			$ 3,100,000
License agreement total fee			$ 15,300,000
Technology transfer agreements fee remainder					The remainder of the fee will be billed as follows: (i) 20 percent in January 2023 and (ii) 20 percent upon the technology transfer completion
Transaction fee price					$ 15,300,000
Bayer Technology Transfer Agreement | Subsequent Event
License, Collaboration and Manufacturing Agreements [Line Items]
License agreement percentage	40.00%
License agreement amount	$ 6,100,000
Bayer Manufacturing Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
License agreement percentage			50.00%
Written acceptance of binding purchase order percentage					50.00%
Bayer Manufacturing Agreement | Maximum
License, Collaboration and Manufacturing Agreements [Line Items]
Manufacturing services			$ 13,100,000
Bayer Manufacturing Agreement | Minimum
License, Collaboration and Manufacturing Agreements [Line Items]
Manufacturing services			$ 6,600,000
Bayer Agreements
License, Collaboration and Manufacturing Agreements [Line Items]
License and collaboration revenue					$ 19,800,000	0
Deferred revenue				$ 61,300,000	51,500,000	$ 61,300,000
Pierre Fabre Commercialization Agreement
License, Collaboration and Manufacturing Agreements [Line Items]
Upfront cash payment received		$ 45,000,000.0
Royalty eligible to receive term after first commercial sale		12 years
License and collaboration revenue					500,000
Development or sales-based milestone payments earned or received					0
Determined upfront payment constituted entire consideration included in transaction price		$ 45,000,000
Upfront payment recognized					0
Pierre Fabre Commercialization Agreement | Long-Term Liabilities
License, Collaboration and Manufacturing Agreements [Line Items]
Deferred revenue					$ 45,000,000.0
Pierre Fabre Commercialization Agreement | Maximum
License, Collaboration and Manufacturing Agreements [Line Items]
Aggregate milestone payments entitle to receive upon achieving certain regulatory and commercial milestones		$ 318,000,000.0
Pierre Fabre Commercialization Agreement | Minimum
License, Collaboration and Manufacturing Agreements [Line Items]
Years of potential to manufacturing and supply					7 years
Years of potential to perform cell-selection services					3 years